ABSTRACT
Objective:To preliminarily understand the living habits, medication taking and treatment status including the therapeutic regimen, compliance and short-term efficacy of patients with chronic atrophic gastritis and erosion in Beijing area.Methods:From April to September in 2019 at Peking Union Medical College Hospital, Peking University Third Hospital and Peking University Shougang Hospital, the outpatients with chronic atrophic gastritis and erosion diagnosed with endoscopy within two weeks before visiting were prospectively included in this non-interventional observation study. Chi square test was used for statistical analysis.Results:A total of 277 patients with chronic atrophic gastritis and erosion had complete follow-up data, of which male patients accounted for 49.8% (138/277). The common initial symptoms of patients with chronic atrophic gastritis and erosion included acid reflux, abdominal distension, epigastric pain and postprandial distension, which accounted for 60.3% (167/277), 59.6% (165/277) , 58.8% (163/277) and 52.3% (145/277), respectively. For treatment, 36.8% (102/277) of the patients only received lifestyle instruction without medication. Among the patients with medication treatment, the short-term efficacy of gastric mucosal protectants+ proton pump inhibitor+ gastro-kinetic agent for abnominal distension, postprandial distention, acid reflux and nausea was highest as compared with other therapeutic regimen, and the differences were statistically significant ( χ2=25.18, 19.49, 13.75, 8.84, all P<0.05). Conclusions:Chronic gastritis with erosion may be caused by a combination of multiple factors, and the symptoms of which lack specific. If necessary, gastroscopy may help the diagnosis. Individualized treatment strategies based on the symptoms of patients is needed for treatment.
ABSTRACT
Objective:To explore the role ofprostaglandin E2 (PGE2) and epidermal growth factor (EGF) in the protective effect ofpolaprezinc on acute gastric mucosal damage.Methods:A total of 30 male SD rats were randomly divided into 3 groups as follows:A blank group,a model group,and a polaprezinc group.The blank group was fed normally.As for the model group and the polaprezinc group,the rats were given 1 mL ethanol (intragastrical administration) first,then they were treated with vehicle (1 mL distilled water) or polaprezinc treatment (100 mg/kg) 1 h later.On the 3rd day,rats in each group were fasting for 24 h before gastric administration.After 2 h of gastric administration,5 mL of intraperitoneal blood was collected,centrifuged and stored at-80 ℃ for the detection of EGF and PGE2.Gastric tissue was collected for anatomic and pathological assessment.Results:Polaprezinc reduced gastric mucosa injury in the polaprezinc group compared to the model group.Compared with the blank group,the levels of PGE2 and EGF in blood serum were significantly decreased in the model group and the polaprezinc group (P＜0.05),while there was no significant difference between the model group and the polaprezinc group (P＞0.05).Conclusion:Polaprezinc can provide effective protection for acute mucosal injury and the underlying mechanism is not directly related to PGE2 and EGF.
ABSTRACT
Introducción: el sangrado digestivo alto constituye uno de los síndromes más frecuentes en servicios de urgencias. La endoscopia oral y los medicamentos antiácidos y protectores de la mucosa gástrica, hacen menos frecuente el empleo de intervenciones quirúrgicas en el manejo del paciente con sangrado digestivo alto. La necesidad del tratamiento quirúrgico no siempre puede obviarse. Objetivo: describir las características clínicas de los pacientes con sangrado digestivo alto atendidos en el Hospital Militar Dr. Joaquín Castillo Duany. Métodos: estudio descriptivo transversal. Universo constituido por 92 pacientes con diagnóstico de sangrado digestivo alto. Variables caracterizadas: edad, sexo, tratamiento médico empleado, técnica quirúrgica utilizada, complicaciones posquirúrgicas y estadía hospitalaria. Resultados: el sangrado digestivo alto fue más frecuente en hombres, con más de 40 años de edad, se les aplicó tratamiento médico, la modalidad más frecuente fue la combinación de antiácidos. Se realizó tratamiento endoscópico al 3,2 por ciento de los pacientes, fueron intervenidos quirúrgicamente el 5,4 por ciento. La mitad de los operados padecía úlcera péptica gástrica. La técnica quirúrgica más empleada fue la gastrostomía y gastrorrafia. La estadía hospitalaria fue menor de 5 días. Conclusiones: se evidenció predominio del sangrado digestivo alto en el sexo masculino y en mayores de 40 años. El tratamiento endoscópico y las intervenciones quirúrgicas representaron un bajo porcentaje. La estadía hospitalaria fue más prolongada en pacientes con complicaciones. Los hallazgos en los que más difieren otras investigaciones radican en el incremento del empleo de la endoscopia oral, en combinación con el uso de antisecretores y en las variantes de técnicas quirúrgicas empleadas(AU)
Introduction: upper Digestive Bleeding is one of the most frequent syndromes in emergency services. Oral endoscopy, antacid and protective gastric mucosal medications make the use of surgical interventions less common in the management of upper digestive bleeding patients. However, the need for surgical treatment cannot always be overlooked. Objective: to describe the clinical characteristics of patients with upper digestive bleeding treated at the Military Hospital Dr. Joaquín Castillo Duany. Methods: cross-sectional descriptive study. A universe of 92 patients with a diagnosis of upper digestive bleeding. Variables characterized: Age, sex, medical treatment, surgical technique used, postoperative complications, and hospital stay. Results: upper digestive bleeding was more frequent in men and in patients over 40 years old. In patients in whom medical treatment was applied, the most frequent modality was the combination of anti-H2 antihistamines and proton pump inhibitors. Endoscopic treatment was performed in 3.2 percent of patients, and 5.4 pèrcent was operated on. Half of the patients underwent gastric peptic ulcer, and the most commonly used surgical technique was gastrostomy. The predominant hospital stay was less than 5 days(AU)
Subject(s)
Humans , Male , Adult , Endoscopy, Gastrointestinal/adverse effects , Gastrointestinal Hemorrhage/diagnosis , Antacids/therapeutic use , Peptic Ulcer Hemorrhage/surgery , Epidemiology, Descriptive , Cross-Sectional StudiesABSTRACT
To observe the clinical efficacy of Huazhuo Jiedu formula in treating chronic erosive gastritis (CEG) patients with syndrome of accumulation of turbidity and toxicity, explore its mechanism by observing the changes in expression levels of hypoxia inducible factor (HIF-1α), vascular endothelial growth factor (VEGF) in serum and gastric mucosa tissues after treatment, and provide theoretical basis for the clinical application of Huazhuo Jiedu formula in treating chronic erosive gastritis. All 70 patient of CEG were randomly divided into control group and treatment group, 35 cases in each group. The patients in control group received Alatan Wuwei Wan, bid, 1 bag/time; while the patients in treatment group were given with Huazhuo Jiedu formula, 1 dose/day. The course of the treatment was 6 months in both groups. The changes in clinical symptoms, gastroscopic signs, pathology and the expression levels of HIF-1α, VEGF, and phosphatase and tensin homolog deleted on chromosome ten (PTEN) in serum and gastric mucosa tissues were observed in both groups. The results showed that treatment group was better than control group in clinical efficacy, gastroscopic efficacy and pathological effect after treatment (<0.05); the levels of HIF-1α and VEGF in serum of treatment group were lower than those in the control group after treatment (<0.05), while the level of PTEN in serum of treatment group was higher than that in the control group after treatment (<0.05); the levels of HIF-1α and VEGF in gastric mucosa tissues in the treatment group were lower than those in the control group after treatment, while the level of PTEN in gastric mucosa tissues in treatment group was higher than that in the control group after treatment (<0.05), with statistically significant differences between these two groups (<0.05). Huazhuo Jiedu formula can improve the clinical symptoms, gastroscopic signs and pathological conditions in CEG patients with syndrome of accumulation of turbidity and toxicity, and the mechanism may be associated with decreasing the expression level of HIF-1α, VEGF and increasing the expression level of PTEN.
ABSTRACT
Introducción: la hemorragia digestiva alta constituye un problema frecuente de salud en el mundo; así se comporta en Cuba, en la provincia Matanzas y en el hospital de estudio. Actualmente es considerada como causa mayor de morbimortalidad. Objetivo: determinar el comportamiento de la hemorragia digestiva alta en el Hospital Militar de Matanzas. Materiales y Métodos: se realizó una investigación descriptiva, en un periodo de cinco años que incluyó a todos los pacientes ingresados con ese diagnóstico, y los que durante su ingreso por otra causa presentaron episodios de hemorragia. El índice de Rockall permitió evaluar la necesidad de cirugía, recidiva y mortalidad. Resultados: la mayoría de los pacientes pertenecieron al grupo de riesgo intermedio. Los hombres fueron los más afectados, el grupo de tercera edad presentó mayor incidencia. La gastritis hemorrágica fue la primera causa de sangrado. La hipertensión arterial resultó ser el factor de riesgo relevante y el tabaquismo el hábito tóxico más frecuente. Conclusiones: como beneficio relevante se demostró la importancia de la endoscopia precoz para el diagnóstico de la causa, tratamiento y pronóstico de la hemorragia. Se observó una buena correlación entre el pronóstico del paciente al ingreso y su estado al final del tratamiento (AU).
Introduction: the high digestive hemorrhage is a frequent health problem in the world; it behaves the same in Cuba, in the province of Matanzas and in the hospital where the study was carried out. Currently it is considered a major cause of morbi-mortality. Objective: to determine the behavior of the high digestive bleeding in the Military Hospital of Matanzas. Materials and Methods: a descriptive research was carried out in a five-year period. It included all the patients admitted with that diagnosis and those who presented episodes of hemorrhage even if they were admitted by any other cause. The Rockall index allowed to assess the necessity of surgery, the recidivism and mortality. Results: most of the patients belonged to the intermediate risk group. Male patients were the most affected one; the group of elder people showed higher incidence. Hemorrhagic gastritis was the first cause of bleeding. Arterial hypertension was the relevant risk factor and smoking the most frequent toxic habit. Conclusions: as a relevant benefit it was showed the importance of precocious endoscopy for the diagnosis of the hemorrhage cause, treatment and prognosis. It was observed a good correlation between the patient´s prognosis at the admission and his status at the end of the treatment (AU).
Subject(s)
Humans , Male , Female , Hematemesis/pathology , Digestive System/pathology , Hemorrhage/epidemiology , Hematemesis/complications , Hematemesis/blood , Endoscopy, Digestive System/methods , Gastric Mucosa/injuries , Hemorrhage/complications , Hemorrhage/diagnosis , Hemorrhage/mortality , Hemorrhage/prevention & control , Hemorrhage/bloodABSTRACT
Objective To investigate the Yangwei granules on Hp positive chronic erosive gastritis and inflammatory factors in the patients with HP negative rate effect. Methods 92 Hp positive patients with chronic erosive gastritis from February 2015 to June 2016 were randomly divided into control group and study group, 46 cases respectively. The control group was given Hp eradication standard scheme; the study group to Yangwei granules treatment. The levels of serum IL-2R, IL-6, TNF-α, and Hp were compared before and after treatment. Results Compared with the control group, serum IL-2R, IL-6, TNF-α alpha of the study group after treatment is lower. The negative rate of Hp in the control group was 69.57%, and the negative rate of Hp in the study group was 89.13%, (P<0.05). The effective rate of the control group was 73.91%, and the effective rate of the study group was 91.31% (P<0.05). Conclusion Yangwei granule can reduce inflammation in patients with Hp positive chronic erosive gastritis the reaction, improve the clinical efficacy and eradication rate of Hp, high safety.
ABSTRACT
Objective To investigate the Yangwei granules on Hp positive chronic erosive gastritis and inflammatory factors in the patients with HP negative rate effect. Methods 92 Hp positive patients with chronic erosive gastritis from February 2015 to June 2016 were randomly divided into control group and study group, 46 cases respectively. The control group was given Hp eradication standard scheme; the study group to Yangwei granules treatment. The levels of serum IL-2R, IL-6, TNF-α, and Hp were compared before and after treatment. Results Compared with the control group, serum IL-2R, IL-6, TNF-α alpha of the study group after treatment is lower. The negative rate of Hp in the control group was 69.57%, and the negative rate of Hp in the study group was 89.13%, (P<0.05). The effective rate of the control group was 73.91%, and the effective rate of the study group was 91.31% (P<0.05). Conclusion Yangwei granule can reduce inflammation in patients with Hp positive chronic erosive gastritis the reaction, improve the clinical efficacy and eradication rate of Hp, high safety.
ABSTRACT
Background: Infection with Helicobacter pylori (H. pylori) is a recognized cause of peptic ulcer and gastritis. Persistence of infection is a definite risk factor for gastric malignancy. Healing of gastritis after eradication of H. pylori reduces the risks of peptic ulcer disease and gastric malignancy. Objectives: To find out the relationship of H. pylori with erosive and nonerosive gastritis, the effect of anti-H. pylori therapy and to compare the effects of anti-H. pylori therapy between two types of gastritis. Materials and Methods: This prospective study was done in the Gastroenterology department of Bangabandhu Sheikh Mujib Medical University, Dhaka from June 2008 to May 2009. One hundred eighty dyspeptic patients were enrolled for the study. Patients with gastritis diagnosed by endoscopy underwent rapid urease test (RUT). RUT positive patients were considered to have H. pylori infection and were treated with triple therapy (omeprazole, amoxycillin and metronidiazole) for 14 days. Treatment responses were assessed by clinical history and also by endoscopic biopsy and RUT. Results of endoscopic findings and RUT after treatment were compared with pretreatment status. Results: Seventy patients completed the treatment and finally could be assessed. Endoscopic findings of 70 patients revealed that 56 (80%) patients had erosive gastritis and 14 (20%) patients had nonerosive gastritis. After treatment, 47 (67.1%) lesions became normal, 16 (22.9%) remained erosive and 7 (10%) non-erosive as before. Out of 14 non-erosive diseases, 7 became normal, while out of 56 erosive diseases 40 became normal. The erosive group responded significantly better than the non-erosive group (c2=32.766, p<0.001). Fifty nine (84.3%) patients with gastritis showed negative urease test after treatment. Conclusion: Strong relation between H. pylori infection and gastritis was found. Majority were antral erosive gastritis. Erosive group responded better than non-erosive group.
ABSTRACT
BACKGROUND/AIMS: Albis(R) is a newly developed drug comprised of ranitidine, bismuth and sucralfate. The aim of the study was to demonstrate the efficacy and safety superiority of Albis(R) compared to Stillen(R) for treating erosive gastritis. METHODS: This study was a randomized, double-blind, multi-center trial. The primary endpoint was 2 weeks of treatment. RESULTS: Of the 229 patients in the intention-to-treat (ITT) population, 87 from the Albis(R), and 96 from the Stillen(R) group were included in the per protocol (PP) analysis. The endoscopic improvement rate was not different between the Albis(R)(R) group and the control in both the PP (42.5%, 39.6%) and ITT (35.3%, 34.5%) populations. The endoscopic cure of erosion was also not different in the Albis(R) group than that in the control group in both the PP (32.3%, 31.3%) and ITT (27.6%, 27.4%) populations. The endoscopic improvement rate for hemorrhage, edema, and erythema were also not different between the two groups in both the PP and ITT populations. No statistically significant differences were observed for adverse events between the two groups. CONCLUSIONS: Half of the approved dose of Albis(R) for peptic ulcers was superior to Stillen(R). A low dosage of Albis(R) is more cost efficient and safe than that of Stillen(R).
Subject(s)
Humans , Bismuth , Edema , Erythema , Hemorrhage , Peptic Ulcer , Ranitidine , SucralfateABSTRACT
Objective To explore effective treatment of uremic hemodialysis patients with chronic helicobacter pylori-negative erosive gastritis.Methods Fourty-eight cases of uremic hemodialysis patients with helicobacter pylori-negative chronic erosive gastritis were diagnosed by detection of helicobacter pylori and endoscopic examination.Fourty-eight patients were randomly divided into two groups,treatment group (24 patients) with oral pantoprazole 40 mg,once a day,combinding with oral Marzulene-S particles,each 0.67 g,three times a day,the control group (24 cases ) only with the dose of pantoprazole treatment.Effect of treatment was compared in these two groups after treatment for 21 days.Results Twenty-one days after treatment,the clinical symptoms of uremic hemodialysis patients with upper gastrointestinal improved in treatment group,and the performance of endoscopic and histopathological has varying degree of improvement.It shows that pantoprazole combined with Marzulene-S treatment group has a significant effect than that single treatment with pantoprazole group.In the treatment group,the total effective rate was 95.83％,however it was 83.33％ in the control group( U =2.716,P ＜ 0.01 ).Repair of mucosal lesions were significantly different between the two groups ( total effective rate 83.33％ vs 45.83％,U =2.349,P ＜ 0.05 ).Conclusion Pantoprazole combined with Marzulene-S therapy has a significant effect on uremic hemodialysis patients with chronic Helicobacter pylori-negative erosive gastritis.
ABSTRACT
BACKGROUND/AIMS: Sulglycotide is a sulphoglycopeptide with antiulcer and cytoprotective activity that is derived from the porcine duodenal mucosa. This study carried out a 3-week single blinded, randomized, multicenter, noninferiority trial to compare the efficacy of oral sulglycotide in treating symptomatic erosive gastritis with that of rebamipide. METHODS: Seventy-three patients with symptomatic erosive gastritis were randomized to receive 3 weeks of treatment with either sulglycotide or rebamipide. The primary efficacy parameter was the endoscopic cure rate and the endoscopic improvement rate, and the secondary parameter was the improvement rate in the dyspepsia symptom scores. RESULTS: Of the 73 patients recruited, 36 received sulglycotide and 37 received rebamipide. The endoscopic cure rate in the sulgycotide and rebamipide group was 29.6% and 25.0% according to per protocol (PP) analysis, respectively (p=0.69). The endoscopic improvement rate in the sulglycotide and rebamipide group was 63.0% and 62.5% according to PP analysis, respectively (p=0.97). The symptomatic improvement rate in the sulgycotide and rebamipide group was 51.9% and 53.1% according to PP analysis, respectively (p=0.74). The result of 90% CIs for the difference in endoscopic cure rate, endoscopic improvement rate and symptom improvement rate between the two groups met the criteria for the non-inferiority of sulglycotide to rebamipide. CONCLUSIONS: Sulglycotide was not inferior to rebamipide in both erosion healing and symptom relief in patients with acute and chronic gastritis.
Subject(s)
Humans , Dyspepsia , Gastritis , Mucous MembraneABSTRACT
Infectious mononucleosis is an EBV-induced infection, and this is a self-limiting clinical syndrome with such characteristics as fever, pharyngitis, headache, splenomegaly, hepatomegaly and multiple lymphadenopathy among children and young adults. On the other hand, EBV infection-induced gastrointestinal symptoms like anorexia, nausea, vomiting, dyspepsia, abdominal pain, gastric bleeding and diarrhea are non-specific signs and there is less of a chance of EBV infection being involved with gastrointestinal disease. Especially, the relation of gastric cancer and gastric lymphoma with EBV infection is well defined, but other EBV-related gastrointestinal diseases have rarely been reported. Therefore, we report here on a case of acute erosive EBV gastritis that was diagnosed as EBV-induced infectious mononucleosis, and this was confirmed by esophagogastroduodenoscopy with biopsy.
Subject(s)
Child , Humans , Young Adult , Abdominal Pain , Anorexia , Biopsy , Diarrhea , Dyspepsia , Endoscopy, Digestive System , Epstein-Barr Virus Infections , Fever , Gastritis , Gastrointestinal Diseases , Hand , Headache , Hemorrhage , Hepatomegaly , Herpesvirus 4, Human , Infectious Mononucleosis , Lymphatic Diseases , Lymphoma , Nausea , Pharyngitis , Splenomegaly , Stomach Neoplasms , VomitingABSTRACT
Infectious mononucleosis is an EBV-induced infection, and this is a self-limiting clinical syndrome with such characteristics as fever, pharyngitis, headache, splenomegaly, hepatomegaly and multiple lymphadenopathy among children and young adults. On the other hand, EBV infection-induced gastrointestinal symptoms like anorexia, nausea, vomiting, dyspepsia, abdominal pain, gastric bleeding and diarrhea are non-specific signs and there is less of a chance of EBV infection being involved with gastrointestinal disease. Especially, the relation of gastric cancer and gastric lymphoma with EBV infection is well defined, but other EBV-related gastrointestinal diseases have rarely been reported. Therefore, we report here on a case of acute erosive EBV gastritis that was diagnosed as EBV-induced infectious mononucleosis, and this was confirmed by esophagogastroduodenoscopy with biopsy.
Subject(s)
Child , Humans , Young Adult , Abdominal Pain , Anorexia , Biopsy , Diarrhea , Dyspepsia , Endoscopy, Digestive System , Epstein-Barr Virus Infections , Fever , Gastritis , Gastrointestinal Diseases , Hand , Headache , Hemorrhage , Hepatomegaly , Herpesvirus 4, Human , Infectious Mononucleosis , Lymphatic Diseases , Lymphoma , Nausea , Pharyngitis , Splenomegaly , Stomach Neoplasms , VomitingABSTRACT
BACKGROUND/AIMS: Phase IIb clinical study of Stillen(TM), a novel cytoprotectant, for gastritis showed 180 mg of Stillen, t.i.d. for 2 weeks results in a significant increase of cure rate when compared with a placebo group. It is reported that antioxidative effect and strengthening the endogenous cytoprotective molecules of the gastric mucosa play a pivotal role for cytoprotective action of Stillen(TM). The aim of this phase III multicenter, double-blind comparative study was to assess the efficacy of Stillen(TM) for the treatment of erosive gastritis. METHODS: Five hundred and twelve patients with erosive gastritis were enrolled and divided into three groups. Each group received 180 mg or 360 mg of Stillen(TM) or 600 mg of cetraxate (Neuer(TM)) t.i.d. for 2 weeks, respectively and a follow-up endoscopic examination for evaluation. RESULTS: Patients treated with 180 mg and 360 mg of Stillen(TM) had a significantly improved endoscopic cure rate of gastritis (55.6% and 57.5%, respectively) compared with patients treated with 600 mg of cetraxate (35.5%, p<0.001). Endoscopic improvement rate was also significantly higher in 180 mg group (67.3%) and 360 mg group (65.0%) of Stillen(TM) treated patients than cetraxate treated group (46.4%, p<0.001). During the study, both Stillen(TM) and cetraxate were well tolerated. CONCLUSIONS: These results clearly demonstrate that Stillen(TM) is an efficacious, safe, and well-tolerated treatment for gastritis.
Subject(s)
Humans , Follow-Up Studies , Gastric Mucosa , GastritisABSTRACT
Objective In order to investigate the comlex course of electricity and mechanism of erosive gastritis(EG) and its relative factors,and to extract gastric motility feature indexes.Methods 30 volunteers of erosive gastritis were selected.The signal processing device was designed by Chongqing University of Posts and Telecommunications.By the means of spectrum analysis technic,the signals could be classified according to the dominant power and dominant frequency.Some indexes such as frequency of EGG and IGM,signal power spectrum and dynamic spectrum,the rates of rhythm and power for the normal EGG and IGM and so on could also be calculated.Results The power ratio in 2~4 cpm was 59.2?4.4,the frequency ratio was 70.4?25.5,the frequency instability coefficient was 0.182?0.059,and the power instability coefficient was 1.576?0.481.The parameters changed signifcantly between health adult and patient(P0.05).Conclusion The results of the experiments show that the method based on the synchronous measurement of EGG and IGM can provide a non-invasive way to investigate and evaluate erosive gastritis corresponding to gastrointestinal physiology and pathology conditions.
ABSTRACT
Objective To evaluate the efficacy and safety of contact endoscopic argon plasma coagulation(APC) for treating protuberant erosive gastritis. Methods 63 patients with protuberant erosive gastritis were randomly divided into groups A and group B, which were treated with non-contact and contact APC, respectively. The efficacy and safety were compared between the two groups. Results There was no significant difference between group A and group B in the efficacy and complication frequency. The curative rates in group A and B were 96.8% and 96.9%, respectively, and only 3 patients had abdominal pain or distension 1 to 3 days after operation, and disappeared within 3 to 7 days after treatment in each group. The numbers of ineffective operation in groups A and B were 284 and 96, respectively. The duration of operation in groups A and B was 11 min and 38 sec,7 min and 22 sec, respectivley. The numbers of accidental injury in group A and B were 137 and 58 times, respectively (all P
ABSTRACT
Objective To study the bile reflux in patients with different kind of chronic gastritis. Methods The changes of intragastric bile reflux during 24 h were assessed by using ambulatory bilirubin monitoring techniques in 45 patients(including 17 patients with chronic superficial gastritis, 21 with chronic erosive gastritis and 7 with chronic atrophic gastritis). Results The total time of intragastric bile reflux(%) was significantly greater in patients with chronic atrophic gastritis(16.2?18.0) and chronic erosive gastritis(14.2?12.1) than that in patients with chronic superficial gastritis(5.3?14.1, P
ABSTRACT
Since amyloidosis is usually diagnosed later in the disease process, a high index of suspicion is therefore necessary for earlier diagnosis. Confirmative diagnosis rests on a biopsy of the involved organ. Gastrointestinal amyloidosis causes a variety of symptoms including intestinal obstruction, ulcers, malabsorption, hemorrhaging, protein loss, diarrhea, anorexia, nausea, vomiting, and dysphagia. We confirmed amyloid deposits in the stomach in three patients with epigastric pain through a biopsy of erosive gastritis documented on a gastrofiberscopy. One patient with primary amyloidosis which had invaded his kidney, stomach, and heart, expired, although aggressive treatment with a pacemaker insertion, peritoneal dialysis, and ventilator care was performed. Another patient with multiple myeloma died on the 38th day, after having started systemic chemotherapy. The other patient with secondary amyloidosis due to rheumatoid arthritis, is currently receiving colchicine at our out patient clinic.
Subject(s)
Humans , Amyloidosis , Anorexia , Arthritis, Rheumatoid , Biopsy , Colchicine , Deglutition Disorders , Diagnosis , Diarrhea , Drug Therapy , Gastritis , Heart , Intestinal Obstruction , Kidney , Multiple Myeloma , Nausea , Peritoneal Dialysis , Plaque, Amyloid , Stomach , Ulcer , Ventilators, Mechanical , VomitingABSTRACT
Objective:To investigate the clinical effect of Weinaian Capsules on chronic erosive gastritis with HP positivity and its effect on HP.Methods: 90 patients with chronic erosive gastritis with HP positivity were divided into 2 groups. 50 cases in the treatment group were given drug Weinaian Capsules orally, 4 capsules each time, 3 times a day. 40 cases in the control group were given drug Compound Aluminum Hydroxide Tablets orally, 2 tablets each time, 3 times a day. Both groups were treated for 6 successive weeks. Results: The effective rates were 92% for the treatment group and 67.5% for the control group ( x 2=23.87,P